PUBLIKACJE

Screening for Type 1 Diabetes Risk in Newborns: The Freder1k Pilot Study in Saxony.
Hommel A, Haupt F, Delivani P, Winkler C, Stopsack M, Wimberger P, Nitzsche K, Heinke S, Naeke A, Ceglarek U, Thiery J, Bergert R, Stadthaus D, Groeger K, Heubner G, Schramm U, Dziambor U, Zirkel A, Kiess W, Mueller I, Lange K, Berner R, Bonifacio E, Ziegler AG; and the Freder1k Study Group. Horm Metab Res. 2018 Jan;50(1):44-49

Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Bonifacio E, Mathieu C, Nepom GT, Ziegler AG, Anhalt H, Haller MJ, Harrison LC, Hebrok M, Kushner JA, Norris JM, Peakman M, Powers AC, Todd JA, Atkinson MA. Diabetologia. 2017 Jan;60(1):35-38.

Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease. Ziegler AG, Bonifacio E, Powers AC, Todd JA, Harrison LC, Atkinson MA. Diabetes. 2016 Nov;65(11):3233-3239.

Primary prevention of beta-cell autoimmunity and type 1 diabetes – The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. Ziegler AG, Danne T, Dunger DB, Berner R, Puff R, Kiess W, Agiostratidou G, Todd JA, Bonifacio E.  Mol Metab. 2016 Feb 22;5(4):255-62.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Diabetes Care. 2015 Oct;38(10):1964-74.

General population screening for type 1 diabetes: has its time come? Insel RA, Dunne JL, Ziegler AG. Curr Opin Endocrinol Diabetes Obes. 2015 Aug;22(4):270-6

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS. JAMA. 2013 Jun 19;309(23):2473-9.